Organon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma
Organon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma Source: Seekingalpha
THE HELITRA EDIT
Tag: downgraded
Organon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma
Organon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma Source: Seekingalpha
Organon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma
Organon downgraded, Amneal upgraded as J.P. Morgan reviews specialty pharma Source: Seekingalpha
Aadi Bioscience downgraded to Neutral, shares fall
Aadi Bioscience downgraded to Neutral, shares fall Source: Seekingalpha
Aadi Bioscience downgraded to Neutral, shares fall (NASDAQ:AADI)
Aadi Bioscience (NASDAQ:AADI) was downgraded to Neutral from Overweight at Piper Sandler after it introduced that mid-stage examine of its stable tumors candidate…
MoonLake Immunotherapeutics downgraded on concerns about lack of near-term catalysts
Biopharma firm MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded to Peer Perform from Outperform at Wolfe Research, citing concerns on overpromised timelines. MLTX down about…
Premier Inc rating downgraded on FY25-26 guidance miss at Benchmark (NASDAQ:PINC)
Healthcare companies supplier Premier Inc (NASDAQ:PINC) was downgraded to Hold from Buy at Benchmark on Monday after the corporate guided its FY25-26 outlook…
MoonLake Immunotherapeutics downgraded on concerns about lack of near-term catalysts
Biopharma firm MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded to Peer Perform from Outperform at Wolfe Research, citing concerns on overpromised timelines. MLTX down about…
Premier Inc rating downgraded on FY25-26 guidance miss at Benchmark (NASDAQ:PINC)
Healthcare companies supplier Premier Inc (NASDAQ:PINC) was downgraded to Hold from Buy at Benchmark on Monday after the corporate guided its FY25-26 outlook…
MoonLake Immunotherapeutics downgraded on concerns about lack of near-term catalysts
Biopharma firm MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded to Peer Perform from Outperform at Wolfe Research, citing concerns on overpromised timelines. MLTX down about…